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alternative. CONCLUSION: Under all circumstances, strategies
using PPIs are optimal for managing patients with GERD.
Emerging concerns around hip fracture and AMI do not signiﬁ-
cantly affect the relative cost-effectiveness performance of alter-
native treatment strategies.
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OBJECTIVE: To determine the cost-utility of PPIs, compared to
alternative gastrointestinal prophylaxis, in the prevention of
GI complications among elderly patients (age  65) taking
nsNSAIDs. METHODS: A cost-utility analysis, from a third-
party payer perspective, was conducted using a decision analy-
tical model over a one year time horizon. We compared:
nsNSAID alone, nsNSAID + PPI (omeprazole, 20 mg od),
nsNSAID + ranitidine (150 mg bid), nsNSAID + ranitidine
(300 mg bid), misoprostol (200 ug bid), and misoprostol
(200 ug qid). Clinical inputs (including ulcer risk, bleeding com-
plications, dyspepsia symptoms), costs, and utilities were derived
from recently published studies. Probabilistic and deterministic
sensitivity analyses were performed to test the robustness of the
results. RESULTS: In elderly patients’ aged 65 y, the incremen-
tal cost-utility ratio (ICUR) of PPIs, relative to nsNSAID alone,
was $320,743 per Quality-adjusted life year (QALY) gained.
Other treatment alternatives (ranitidine and misoprostol) were
dominated. The ICUR of PPI, relative to nsNSAID alone, was
$207,604 per QALY gained in patients aged >75 y. In patients
taking concomitant low-dose aspirin, ICURs for PPI therapy
were $190,943 and $117,944 per QALY gained in patients’ aged
65 y and aged75 y, respectively. In patients’ aged65 y with
a history of a complicated or uncomplicated ulcer, ICURs of
$25,662 and $45,688 were observed, respectively. CONCLU-
SION: Routine prescription of PPIs in all elderly patients (age
65 y) taking nsNSAIDs may not be warranted in a health care
system with ﬁnite resources, as ICURs exceeded commonly cited
thresholds in the range $50,000–$100,000 per QALY gained.
However, co-prescribing PPIs among all elderly patients (age
65 y) taking nsNSAIDs and with a history of a complicated or
uncomplicated ulcer may be considered good value for money,
as ICURs are less than $50,000 per QALY gained.
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OBJECTIVE: Examine medication utilization for gastro-
esophageal reﬂux disease (GERD) in a community-based setting.
Assess disparities in types of medications used and frequency of
use related to severity of symptoms, race, education, employ-
ment, and income. METHODS: A questionnaire based upon
previous work (Srinivansin, J Clin Gastro) was developed to
assess self-reported GERD prevalence and medication utilization
and was translated into Chinese and Spanish. We worked with
community and faith-based leaders to identify events for data
collection. GERD prevalence and medication usage in four ethnic
groups (White, Black, Asian, Hispanic) were compared, control-
ling for age, gender and other demographic variables. Descriptive
and multivariate analyses were done using SAS 9.1. RESULTS:
Of the 34.6% (307/1172) of respondents reporting at least
weekly heartburn, 60.6% took over-the-counter medication,
56.4% took prescription (Rx) medication and 12.7% took no
medications. Whites had a signiﬁcantly higher rate of OTC uti-
lization at 68.8%, followed by Hispanics, Blacks, and Asians at
61.1%, 60.2%, and 35.5%, respectively (P = 0.0127). Whites
were the lowest utilizers of Rx medications compared to the
other ethnicities. For those taking prescription Proton Pump
Inhibitors (PPIs), (N = 131) 51.7% took them 5 to 7 times per
week. Participants with at least weekly and daily heartburn were
more likely to take PPIs 5–7 times per week (P = .0098 and
P = 0.0056, respectively). Subjects with a diagnosis of GERD by
a physician were more likely to take their prescription PPIs 5 to
7 times per week compared to those claiming no diagnosis, 60%
v. 37.3%, respectively (P = 0.0111). CONCLUSION: We found
signiﬁcant variation in the use of OTC and RX medications for
GERD by ethnicity. Only half of patients taking prescription PPIs
took them 5–7 times per week. Future research should focus on
improving communication of GERD diagnosis to patients and
recommended use of prescription PPIs in the absence of a diag-
nosis for GERD.
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OBJECTIVE: Several biologics, especially TNF antagonists, have
been established as effective therapy for Crohn’s disease (CD).
Adherence to biologic therapy is thought to be important for
optimal outcomes. This analysis retrospectively quantiﬁed the
impact of non-adherence to inﬂiximab maintenance therapy on
medical service use by CD patients. METHODS: CD patients on
inﬂiximab maintenance therapy were identiﬁed from the Inte-
grated Healthcare Information Services claims database (cover-
ing approximately 35 million managed care lives from January 1,
1999 to June 30, 2006) if they had 4 inﬂiximab infusions (with
intervals 12 weeks between the ﬁrst four infusions) in the ﬁrst
year following inﬂiximab initiation. Non-adherence was deﬁned
as total number of inﬂiximab infusions <7 in the ﬁrst year (the
expected number is 8 if patients follow the labeled schedule).
One-year medical service utilization and costs (excluding inﬂix-
imab drug/administration costs) were analyzed. Descriptive sta-
tistics and multivariate regressions adjusted for confounders
were performed. RESULTS: A total of 647 CD patients were
identiﬁed. The 1-year non-adherence rate was 35.9%. Descrip-
tive statistics demonstrated that non-adherent patients were
more frequently hospitalized, and incurred greater 1-year costs
for hospitalization and total medical services (p = 0.05 for all
comparisons). Adjusted multivariate regression analyses demon-
strated that, compared with adherent patients, non-adherent
patients had greater risks of hospitalization (odds ratios were
2.3 for CD-related; 2.5 for all-cause, both p < 0.001); and
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